A generic alternative indicated for HIV care. This specific combination therapy supports the suppression of viral replication and assists with maintaining long-term immune system stability.
Designed to manage HIV-1 by addressing multiple viral replication steps to support immune health and mitigate the risk of clinical disease progression effectively.
Mechanism of Action
This three-drug combo works by blocking two different enzymes: Integrase and Reverse Transcriptase. By attacking the virus at multiple points in its life cycle, it effectively stops it from replicating and infecting healthy cells.
Route of Administration
Oral
Onset Time
Steady state in 5 days
Duration
24 hours
Contraindications
Positive HLA-B*5701 allele (hypersensitivity risk), Concurrent use with dofetilide, Moderate to severe liver impairment
Severe Adverse Events
Severe hypersensitivity reactions (Abacavir), Lactic acidosis, Severe liver injury, Hepatitis B flare-up after stopping, Immune reconstitution syndrome
Information for Triumeq is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
